ArticleTheranostics2021
Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.Molecular cancer therapeutics · 2026Article
- LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma.European journal of medical research · 2025Article
- Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer.Cancer science · 2025Article
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases.DNA repair · 2025Review
- LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers.Molecular cancer therapeutics · 2025Article
- Redundant but essential functions of PARP1 and PARP2 in DNA ligase I-independent DNA replication.Nucleic acids research · 2024Article
- Impact of polβ/XRCC1 Interaction Variants on the Efficiency of Nick Sealing by DNA Ligase IIIα in the Base Excision Repair Pathway.Journal of molecular biology · 2024Article
- Article
- Mammalian DNA ligases; roles in maintaining genome integrity.Journal of molecular biology · 2024Review
- Incorporating genotype information in a precise prediction model for platinum sensitivity in epithelial ovarian cancer.Frontiers in oncology · 2024Article
- hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.Molecular cancer · 2023Article
- Distinct functions of EHMT1 and EHMT2 in cancer chemotherapy and immunotherapy.bioRxiv : the preprint server for biology · 2023Article
- Unchanged PCNA and DNMT1 dynamics during replication in DNA ligase I-deficient cells but abnormal chromatin levels of non-replicative histone H1.Scientific reports · 2023Article
- Feature selection translates drug response predictors from cell lines to patients.Frontiers in genetics · 2023Article
- Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers.NPJ precision oncology · 2022Article
- Exploiting replication gaps for cancer therapy.Molecular cell · 2022Review
- Association of Polymorphisms in NHEJ Pathway Genes with HIV-1 Infection and AIDS Progression in a Northern Chinese MSM Population.Disease markers · 2022Article
- DNA damage repair-related gene signature predicts prognosis and indicates immune cell infiltration landscape in skin cutaneous melanoma.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 3 countries.
Reem AliNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Muslim AlabdullahNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Mashael AlgethamiNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Adel AlblihyNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Islam MiligyDepartment of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51PB, UK.
Ahmed ShoqafiNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Katia A MesquitaNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
Tarek Abdel-FatahDepartment of Oncology, Nottingham University Hospitals, City Hospital Campus, Nottingham NG5 1PB, UK.
Stephen Yt ChanDepartment of Oncology, Nottingham University Hospitals, City Hospital Campus, Nottingham NG5 1PB, UK.
Pei Wen ChiangDepartment of Obstetrics & Gynaecology, Queens Medical Centre, Nottingham University Hospitals, Nottingham NG7 2UH, UK.
Nigel P MonganFaculty of Medicine and Health Sciences, Centre for Cancer Sciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire LE12 5RD, UK.
Emad A RakhaDepartment of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51PB, UK.
Alan E TomkinsonDepartment of Internal Medicine, Division of Molecular Medicine, Health Sciences Center, The University of New Mexico, Albuquerque, NM 87102, USA.
Srinivasan MadhusudanNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
University of Nottingham · GBNottingham University Hospitals NHS Trust · GB
Funding
Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI WALTER J. CHAZIN · 2001 to 2026
$89.6MWOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1MRoles of LIG3 and XRCC1 genes in genome stability.R01ES012512 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Alan E Tomkinson · 2004 to 2026
$6.3MCELLULAR FUNCTIONS OF EUKARYOTIC LIGASESR01GM047251 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DAVIS, ANTHONY J, TOMKINSON, ALAN E · 1998 to 2021
$4.7MROLES OF DNA LIGASE I IN MAMMALIAN DNA METABOLISMR01GM057479 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI TOMKINSON, ALAN E · 2000 to 2017
$3.7MSYNTHETIC APPLICATIONS OF SET PHOTOCHEMISTRYR01GM027251 · NIGMS · UNIVERSITY OF NEW MEXICO · PI MARIANO, PATRICK S · 1985 to 2004
$1.1MNCI NIH HHS P01 CA092584NCI NIH HHS P30 CA118100NIEHS NIH HHS R01 ES012512NIGMS NIH HHS R01 GM027251NIGMS NIH HHS R01 GM047251NIGMS NIH HHS R01 GM057479
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultCarcinoma, Ovarian EpithelialCell Line, TumorCisplatinDNA Ligase ATPDrug Resistance, NeoplasmFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLigasesMembrane GlycoproteinsMiddle AgedOvarian NeoplasmsPrognosisCisplatinDNA Ligase ATPLIG1 protein, humanLIG4 protein, humanLigasesLRIG2 protein, humanMembrane GlycoproteinsX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanDNA repairLIG1LIG1 inhibitorLIG3LIG4Ovarian cancerPredictive bimarkerPrognosticsSynthetic lethality
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.